TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32592973

Group type: EXPERIMENTAL
Intervention: 80-kVp protocol with 60 ml CM and ASIR-V
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 80-kVp protocol with 45 ml CM and ASIR-V
Number of subjects: 119

Group type: COMPARATOR
Intervention: 120-kVp protocol with 60 ml CM and filtered back projection
Number of subjects: 119
Study: 36031855

Group type: EXPERIMENTAL
Intervention: Music therapy delivered using an MP3 player and headphones
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-music group (control)
Number of subjects: 90
Study: 32096197

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) using CalliSpheres beads loading with arsenic trioxide (CBATO)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional TACE (cTACE) with arsenic trioxide (ATO)
Number of subjects: 86
Study: 37286390

Group type: EXPERIMENTAL
Intervention: 12-week standardised exercise program including head lifts, abdominal curl‐ups and twisted abdominal curl‐ups 5 days a week
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 33539062

Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% topical solution applied once daily for 18-24 months
Number of subjects: 101
Study: 32646282

Group type: EXPERIMENTAL
Intervention: Recreational judo training (JT) for 12 weeks, 60-min sessions, 2 times/week at 65-75% maximal heart rate
Number of subjects: 35
Study: 35245284

Group type: EXPERIMENTAL
Intervention: PermaNet insecticide-treated window curtains (ITCs)
Number of subjects: 6223

Group type: EXPERIMENTAL
Intervention: Permanent insecticide-treated water storage jar covers (ITJCs)
Number of subjects: 6223

Group type: EXPERIMENTAL
Intervention: Combination of ITCs and ITJCs
Number of subjects: 6223

Group type: COMPARATOR
Intervention: No insecticide treated materials (ITMs)
Number of subjects: 6223

Group type: COMPARATOR
Intervention: External control (15 clusters located at least 5km from the study site)
Number of subjects: 6223
Study: 32178608

Group type: EXPERIMENTAL
Intervention: 19,20‐dihydroervahanine A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 19,20‐dihydrotabernamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8‐Clavandurylkaempferol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Na‐methylepipachysamine D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ebeiedinone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dictyophlebine
Number of subjects: 0
Study: 33964555

Group type: EXPERIMENTAL
Intervention: Real indoor air filtration
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham indoor air filtration
Number of subjects: 57
Study: 35405088

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus pertuzumab plus paclitaxel
Number of subjects: 134

Group type: COMPARATOR
Intervention: Trastuzumab plus pertuzumab
Number of subjects: 134
Study: 32699904

Group type: EXPERIMENTAL
Intervention: Sandoz rituximab (SDZ‐RTX)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Reference rituximab (Ref‐RTX)
Number of subjects: 312
Study: 32122397

Group type: EXPERIMENTAL
Intervention: Prophylactic swallowing exercises (PSE) at home
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Prophylactic swallowing exercises (PSE) at home with continuous counseling through an app
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Prophylactic swallowing exercises (PSE) with face-to-face therapy by a speech and language pathologist
Number of subjects: 150
Study: 33729038

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) plus 36 sessions of group exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 33370803

Group type: EXPERIMENTAL
Intervention: aHBP
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: vHBP
Number of subjects: 50
Study: 35381576

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemotherapy
Number of subjects: 844

Group type: COMPARATOR
Intervention: Cetuximab-chemotherapy
Number of subjects: 844
Study: 33711991

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) 2 mg/kg, subcutaneous, twice weekly for 6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 20
Study: 35876371

Group type: EXPERIMENTAL
Intervention: Reinforced stapler (RS)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard stapler (SS)
Number of subjects: 199
Study: 35421223

Group type: EXPERIMENTAL
Intervention: Continuous WTN (25 dB(A)) throughout the night
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: WTN (25 dB(A)) only during periods of established sleep
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: WTN (25 dB(A)) only during periods of wake or light N1 sleep
Number of subjects: 68

Group type: COMPARATOR
Intervention: Quiet control night (19 dB(A) background laboratory noise)
Number of subjects: 68
Study: 34398641

Group type: EXPERIMENTAL
Intervention: Double-row fixation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Single-row fixation
Number of subjects: 90
Study: 32814717

Group type: EXPERIMENTAL
Intervention: Reduced concentrations of cardiomyocyte PITX2
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Elevated BMP10 plasma concentrations
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Left atrial size
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Nonparoxysmal AF
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: BMP10 compared to 11 other cardiovascular biomarkers
Number of subjects: 359
Study: 34346910

Group type: EXPERIMENTAL
Intervention: HIIT-A (aerobic-only high-intensity interval training)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: HIIT-AR (aerobic/resistance high-intensity interval training)
Number of subjects: 58

Group type: COMPARATOR
Intervention: CG (resting control group)
Number of subjects: 58
Study: 34508594

Group type: EXPERIMENTAL
Intervention: Sarilumab monotherapy (200 mg every 2 weeks)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Sarilumab plus methotrexate
Number of subjects: 583
Study: 33735463

Group type: EXPERIMENTAL
Intervention: Rocking therapy for a minimum of 20 minutes daily
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group with same type of chair but without rocking therapy
Number of subjects: 152
Study: 36051928

Group type: EXPERIMENTAL
Intervention: DPL combined with clarithromycin
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study: 34897099

Group type: EXPERIMENTAL
Intervention: Venglustat
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 32143644

Group type: EXPERIMENTAL
Intervention: Mothers and Babies Program (MB) delivered by paraprofessional staff
Number of subjects: 874

Group type: COMPARATOR
Intervention: Mothers and Babies Program (MB) delivered by mental health professionals
Number of subjects: 874
Study: 35436209

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI)
Number of subjects: 50
Study: 33789909

Group type: EXPERIMENTAL
Intervention: Food-based approach (FBA)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Carbohydrate counting (CC)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 159
Study: 32215726

Group type: EXPERIMENTAL
Intervention: Potato-based products (1.6 g kg-1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sport supplements (1.6 g kg-1)
Number of subjects: 16
Study: 35332058

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: adalimumab 40 mg every other week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once daily (switched from placebo)
Number of subjects: 0
Study: 35341943

Group type: EXPERIMENTAL
Intervention: Ayurcov (three doses on Day 1 as an adjuvant to standard of care)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 120
Study: 33764681

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted lumbar punctures
Number of subjects: 62
Study: 32067585

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 35445819

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sleep deprivation
Number of subjects: 15
Study: 33271975

Group type: EXPERIMENTAL
Intervention: Psycho-educational group intervention (AMIN)
Number of subjects: 0
Study: 35553043

Group type: EXPERIMENTAL
Intervention: NAC-GED 5%
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: NAC-GED 2%
Number of subjects: 450

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Adverse Events (AEs)
Number of subjects: 450
Study: 34644765

Group type: EXPERIMENTAL
Intervention: WALANT
Number of subjects: 78

Group type: COMPARATOR
Intervention: IVRA
Number of subjects: 78
Study: 32349059

Group type: EXPERIMENTAL
Intervention: 15 mg/kg loading dose intravenous infusion 30 minutes before surgery and again 3 hours later (Group C)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 15 mg/kg loading dose intravenous infusion 30 minutes before surgery (Group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 0.9% normal saline solution without TXA (Group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: TXA (both Group B and Group C)
Number of subjects: 150
Study: 34280552

Group type: EXPERIMENTAL
Intervention: Mailed Fecal Immunochemical Test (FIT) outreach with advanced notification call and informational postcard
Number of subjects: 10771

Group type: EXPERIMENTAL
Intervention: Mailed Fecal Immunochemical Test (FIT) outreach
Number of subjects: 10771

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 10771
Study: 34253077

Group type: EXPERIMENTAL
Intervention: Amplification of Positivity Therapy (AMP) for alcohol use (AMP‐A) delivered in 11 individual sessions
Number of subjects: 8
Study: 34053752

Group type: EXPERIMENTAL
Intervention: Patient-Specific Instrumentation (PSI)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 173
Study: 32039852

Group type: EXPERIMENTAL
Intervention: Structured Physical Exercise Program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Social Stimulation Program
Number of subjects: 70
Study: 34648061

Group type: EXPERIMENTAL
Intervention: Mind-body prehabilitation intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Exercise prehabilitation intervention
Number of subjects: 49
Study: 36202588

Group type: EXPERIMENTAL
Intervention: Intrapartum-related perinatal mortality among caesarean births
Number of subjects: 5134

Group type: EXPERIMENTAL
Intervention: Adjusted mortality rates after case mix adjustment
Number of subjects: 5134

Group type: EXPERIMENTAL
Intervention: Adjusted mortality rates after adjusting for caesarean care components
Number of subjects: 5134
Study: 33421309

Group type: EXPERIMENTAL
Intervention: Canagliflozin added to teneligliptin (COMB group)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Teneligliptin switched to canagliflozin (SWITCH group)
Number of subjects: 99
Study: 33034628

Group type: EXPERIMENTAL
Intervention: Fluorescence visualization-guided surgery
Number of subjects: 443

Group type: COMPARATOR
Intervention: Non-fluorescence visualization-guided surgery (Control)
Number of subjects: 443
Study: 35617945

Group type: EXPERIMENTAL
Intervention: Random‐Errorless group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Random group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Random‐Errorful group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Errorless conditions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Errorful conditions
Number of subjects: 120
Study: 33554268

Group type: EXPERIMENTAL
Intervention: Gentamicin ointment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 20
Study: 32690164

Group type: EXPERIMENTAL
Intervention: Lifestyle modification education based on health belief model
Number of subjects: 82
Study: 35670369

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 33788162

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 1627

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1627
Study: 36294463

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 32540584

Group type: EXPERIMENTAL
Intervention: High-volume corticosteroid injection (1 mL triamcinolone acetonide/40 mg, 9 mL anaesthetic agents)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Low-volume corticosteroid injection (1 mL triamcinolone acetonide/40 mg)
Number of subjects: 136
Study: 35860380

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) via colonoscopy with donor stool, followed by three enemas over 3 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral probiotics (control group).
Number of subjects: 0
Study: 33570978

Group type: EXPERIMENTAL
Intervention: Hybrid mobile intervention targeting MVPA and FV
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Hybrid mobile intervention targeting SED and FAT
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Hybrid mobile intervention targeting behaviors
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: MBC2 trial examining correlations
Number of subjects: 204
Study: 32698457

Group type: EXPERIMENTAL
Intervention: Pistachio group (1.5 oz/day or 42 g/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (behavioral weight loss intervention only)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pistachio group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 34014615

Group type: EXPERIMENTAL
Intervention: Deep learning method for RET enumeration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual method (control)
Number of subjects: 40
Study: 32597580

Group type: EXPERIMENTAL
Intervention: Phenazopyridine (200 mg, 2 tablets of 100 mg p.o., once)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (same administration scheme as phenazopyridine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Number of subjects: 60
Study: 35318234

Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation (tVNS) for 20 min/day for 12 weeks
Number of subjects: 156

Group type: COMPARATOR
Intervention: Sham transcutaneous vagus nerve stimulation (tVNS) with no electric current for 20 min/day for 12 weeks
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Active tVNS
Number of subjects: 156

Group type: COMPARATOR
Intervention: Sham tVNS
Number of subjects: 156
Study: 32329767

Group type: EXPERIMENTAL
Intervention: Intranasal Naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular Naloxone
Number of subjects: 0
Study: 33774878

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33526730

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day (group 1, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group 2, n=30)
Number of subjects: 60
Study: 35413714

Group type: EXPERIMENTAL
Intervention: A. annua extracts sublingual immunotherapy (SLIT) with pharmacotherapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Symptomatic drugs only (Control)
Number of subjects: 88
Study: 33641848

Group type: EXPERIMENTAL
Intervention: m-learning intervention
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (no m-learning intervention)
Number of subjects: 190
Study: 32059728

Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Exercise (CARE) program during chemotherapy
Number of subjects: 301
Study: 35796876

Group type: EXPERIMENTAL
Intervention: Super-supraglottic swallow
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Effortful swallow
Number of subjects: 20
Study: 32434467

Group type: EXPERIMENTAL
Intervention: Practice facilitation to promote screening, counseling, and MAT
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (6-month delay in intervention)
Number of subjects: 125
Study: 33307101

Group type: EXPERIMENTAL
Intervention: Anodal stimulation to the prefrontal cortex
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cathodal stimulation to the inferior parietal lobule
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 150
Study: 32206987

Group type: EXPERIMENTAL
Intervention: Xuezhitong (XZT) 2700 mg daily
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) 1200 mg daily
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study: 36030033

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy (BBT)
Number of subjects: 185
Study: 34465810

Group type: EXPERIMENTAL
Intervention: Genetically determined SMOX activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: SMOX locus (rs1741315)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GWAS of spermidine/spermine ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: PheWAS of rs1741315
Number of subjects: 0
Study: 33302685

Group type: EXPERIMENTAL
Intervention: TNF-α antagonist etanercept 25 mg subcutaneous injection two times a week for two weeks
Number of subjects: 1
Study: 35881851

Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CBD
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: THC+CBD
Number of subjects: 18
Study: 34515985

Group type: EXPERIMENTAL
Intervention: VP-102 (0.7% w/v cantharidin) with 6-h occlusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VP-102 (0.7% w/v cantharidin) with 24-h occlusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 32270482

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 551

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 551
Study: 35962657

Group type: EXPERIMENTAL
Intervention: Nasal high-flow therapy
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard care (no nasal high-flow therapy or supplemental oxygen)
Number of subjects: 202
Study: 34225270

Group type: EXPERIMENTAL
Intervention: Cyclic steroid‐cyclophosphamide regimen (modified Ponticelli protocol)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Rituximab (1 g × 2)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 74
Study: 35322972

Group type: EXPERIMENTAL
Intervention: Caudal epidural steroid injection (CESI)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Transforaminal epidural steroid injection (TFESI)
Number of subjects: 56
Study: 32594305

Group type: EXPERIMENTAL
Intervention: Rectal omeprazole (1 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral omeprazole (1 mg/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Rectal omeprazole
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral omeprazole
Number of subjects: 17
Study: 32870520

Group type: EXPERIMENTAL
Intervention: Total diet replacement (825–853 kcal/day, 3–5 months, shakes/soups)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Weight loss (kg)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Quality of life measures (anxiety/depression)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Baseline HbA1c
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Age and sex
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Antidepressants prescription
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Weight loss maintenance support (2 years)
Number of subjects: 149
Study: 32546211

Group type: EXPERIMENTAL
Intervention: 4 °C hypothermic perfusion
Number of subjects: 106

Group type: COMPARATOR
Intervention: 24 °C control
Number of subjects: 106
Study: 36064598

Group type: EXPERIMENTAL
Intervention: Active recharge burst spinal cord stimulation (SCS)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Passive recharge burst spinal cord stimulation (SCS)
Number of subjects: 94
Study: 32298407

Group type: EXPERIMENTAL
Intervention: Advice from a doctor or health professional to improve diet
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Advice from a doctor or health professional to improve exercise
Number of subjects: 193
Study: 32198596

Group type: EXPERIMENTAL
Intervention: MSC therapy (Men‐MSCs)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Routine ICSI
Number of subjects: 31
Study: 34777570

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with repeated transcranial magnetic stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional paralysis treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repeated transcranial magnetic stimulation alone
Number of subjects: 0
Study: 32444033

Group type: EXPERIMENTAL
Intervention: Lavender herbal tea (2 g teabag, 2 times daily for 2 weeks)
Number of subjects: 60
Study: 37608258

Group type: EXPERIMENTAL
Intervention: Salvage MRgRT in 5 fractions (32.5 Gy over 2 weeks)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Salvage MRgRT in 20 fractions (55 Gy over 4 weeks)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Safety endpoints (GI and GU symptoms)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Efficacy endpoints
Number of subjects: 136
Study: 32579066

Group type: EXPERIMENTAL
Intervention: Pyrazole based sulfonamides; specific compounds include NMT106, NMT157, NMT187, NMT236; dosage and duration not specified.
Number of subjects: 0
Study: 33801767

Group type: EXPERIMENTAL
Intervention: High-flavanol cocoa (150 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-flavanol cocoa (<4 mg (‐)‐epicatechin)
Number of subjects: 30
Study: 32163799

Group type: EXPERIMENTAL
Intervention: 200 ml of grape juice
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 75 g glucose
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 75 g maltodextrin
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no sugar administration)
Number of subjects: 103
Study: 34864766

Group type: EXPERIMENTAL
Intervention: Robotic locomotor training (60-min sessions, 3× per week, over 24 wks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Activity-based training (60-min sessions, 3× per week, over 24 wks)
Number of subjects: 16